Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life.

Fecha de publicación: 01/01/2023

Autores de IIS La Fe

Irene Martínez Torres

Autor

Participantes ajenos a IIS La Fe

Santos-Garcia, Diego
de Deus Fonticoba, Teresa
Cores Bartolome, Carlos
Feal Painceiras, Maria J.
Íñiguez-Alvarado MC
Garcia Diaz, Iago
Jesus, Silvia
Buongiorno MT
Planellas, Lluis
Cosgaya, Marina
Garcia Caldentey, Juan
Caballol, Nuria
Legarda, Ines
Hernandez Vara, Jorge
Cabo, Iria
Lopez Manzanares, Lydia
Gonzalez Aramburu, Isabel
Avila Rivera, Maria A.
Gomez Mayordomo, Victor
Nogueira, Victor
Puente, Victor
Dotor Garcia-Sotos, Julio
Borrue, Carmen
Solano Vila, Berta
Alvarez Sauco, Maria
Vela, Lydia
Escalante, Sonia
Cubo, Esther
Carrillo Padilla, Francisco
Martinez Castrillo, Juan C.
Sanchez Alonso, Pilar
Alonso Losada, Maria G.
Lopez Ariztegui, Nuria
Gaston, Itziar
Kulisevsky, Jaime
Menendez Gonzalez, Manuel
Seijo, Manuel
Ruiz Martinez, Javier
Valero, Caridad
Kurtis, Monica
Gonzalez Ardura, Jessica
Alonso Redondo, Ruben
Ordas, Carlos
Lopez Diaz, Luis M.
McAfee, Darrian
Calopa, Matilde
Carrillo, Fatima
Escamilla Sevilla, Francisco
Freire-Alvarez, Eric
Gomez Esteban, Juan Carlos
Garcia Ramos, Rocio
Luquín MRI
Sesar Ignacio, Angel
Martinez-Martin, Pablo
Mir, Pablo
COPPADIS Study Group

Grupos

Unidad mixta de investigación en enfermedades raras (CIPF)

Leader

José María Millán Salvador

Abstract

BACKGROUND: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD). OBJECTIVE: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity. METHODS: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL:1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8). RESULTS: Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage was:stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages. CONCLUSION: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD.